These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment]. Sicińska J; Rudnicka L Pol Merkur Lekarski; 2008 Aug; 25(146):196-200. PubMed ID: 18942347 [TBL] [Abstract][Full Text] [Related]
23. Treatments for pulmonary arterial hypertension. Liu C; Liu K; Ji Z; Liu G Respir Med; 2006 May; 100(5):765-74. PubMed ID: 16549344 [TBL] [Abstract][Full Text] [Related]
24. [Advances in the treatment of scleroderma]. Marquet R; Vilardell M Med Clin (Barc); 1984 Jun; 83(2):74-7. PubMed ID: 6147448 [No Abstract] [Full Text] [Related]
25. [Renal involvement in systemic sclerosis]. Guerini S; Cavazzana I; Venturelli C; Rozzi M; Turina S; Sottini L; Tardanico R; Franceschini F; Scolari F G Ital Nefrol; 2007; 24(4):295-310. PubMed ID: 17659501 [TBL] [Abstract][Full Text] [Related]
26. [Cyclophosphamide pulse therapy for pediatric systemic sclerosis]. Iwata N; Miyamae T; Imagawa T; Katakura S; Mori M; Aihara Y; Yokota S; Kondo M; Sasaki T; Ikezawa Y Ryumachi; 2003 Oct; 43(4):660-6. PubMed ID: 14598659 [TBL] [Abstract][Full Text] [Related]
27. Management of systemic sclerosis. Lim IG; Schrieber L Isr Med Assoc J; 2002 Nov; 4(11 Suppl):953-7. PubMed ID: 12455189 [No Abstract] [Full Text] [Related]
28. [Treatment of interstitial pulmonary fibrosis with D-penicillamine in progressive scleroderma: a long-term study (author's transl)]. Bröll H; Tausch G; Eberl R Wien Klin Wochenschr; 1976 Apr; 88(9):292-5. PubMed ID: 973388 [TBL] [Abstract][Full Text] [Related]
29. Cyclophosphamide in scleroderma lung disease. Sullivan KM; McSweeney PA; Nash RA N Engl J Med; 2006 Sep; 355(11):1173-4; author reply 1174. PubMed ID: 16977701 [No Abstract] [Full Text] [Related]
32. [Evidence-based therapy of systemic sclerosis]. Genth E Z Rheumatol; 2001 Dec; 60(6):464-8. PubMed ID: 11826742 [TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071 [TBL] [Abstract][Full Text] [Related]
34. Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue. Prescrire Int; 2006 Oct; 15(85):177-9. PubMed ID: 17128524 [TBL] [Abstract][Full Text] [Related]
35. [Prognosis and treatment of scleroderma]. Crickx B; Belaich S Ann Med Interne (Paris); 1984; 135(8):624-9. PubMed ID: 6529058 [TBL] [Abstract][Full Text] [Related]
36. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
37. [Pulmonary hypertension in left heart disease]. Opitz CF; Gläser S; Ewert R Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S167-9. PubMed ID: 19718607 [TBL] [Abstract][Full Text] [Related]
38. Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study. Bendayan D; Shitrit D; Kramer MR Respirology; 2008 Nov; 13(6):916-8. PubMed ID: 18811891 [TBL] [Abstract][Full Text] [Related]
39. Cyclophosphamide in scleroderma lung disease. Andreu JL; Silva L N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16977700 [No Abstract] [Full Text] [Related]
40. Cyclophosphamide in scleroderma lung disease. Kuschner WG N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16971726 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]